Literature DB >> 1793022

15-Deoxyspergualin (15-DOS) for therapy in an animal model of multiple sclerosis (MS): disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE).

H U Schorlemmer1, F R Seiler.   

Abstract

We examined the therapeutic effect of 15-DOS in the two models of acute and chronic relapsing EAE in Lewis rats. In the first model adult rats developed an acute severe EAE and by day 16 all animals died. Lewis rats treated with 15-DOS showed a delayed and reduced onset of clinical symptoms and mortality was prevented. In the second model Lewis rats (aged animals) developed a chronic relapsing EAE with up to three relapses. The second and third episodes were both milder and shorter in duration. All animals treated with 15-DOS survived the delayed first attack and developed no further relapses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1793022     DOI: 10.1007/bf01993265

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  5 in total

1.  Treatment of acute rejection episodes and induction of tolerance in rat skin allotransplantation by 15-deoxyspergualin.

Authors:  H U Schorlemmer; G Dickneite; F R Seiler
Journal:  Transplant Proc       Date:  1990-08       Impact factor: 1.066

2.  Relationship of experimental allergic encephalomyelitis to human disease.

Authors:  S Levine
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1971

3.  Synthesis and antitumor activity of spergualin analogues. III. Novel method for synthesis of optically active 15-deoxyspergualin and 15-deoxy-11-O-methylspergualin.

Authors:  Y Umeda; M Moriguchi; K Ikai; H Kuroda; T Nakamura; A Fujii; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

4.  Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat.

Authors:  C Feurer; D E Prentice; S Cammisuli
Journal:  J Neuroimmunol       Date:  1985-12       Impact factor: 3.478

5.  The encephalomyelitic activity of myelin isolated by ultracentrifugation.

Authors:  R H LAATSCH; M W KIES; S GORDON; E C ALVORD
Journal:  J Exp Med       Date:  1962-04-01       Impact factor: 14.307

  5 in total
  4 in total

Review 1.  Prevention of transplant rejection: current treatment guidelines and future developments.

Authors:  N Perico; G Remuzzi
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

2.  Immunosuppressive therapy of organ-specific nephritic autoimmune diseases with 15-deoxyspergualin.

Authors:  H U Schorlemmer; H P Neubauer; J Czech; G Dickneite
Journal:  Agents Actions       Date:  1993

3.  Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat.

Authors:  S Jung; K V Toyka; H P Hartung
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

Review 4.  NF-κB in neurodegenerative diseases: Recent evidence from human genetics.

Authors:  Barbara Kaltschmidt; Laureen P Helweg; Johannes F W Greiner; Christian Kaltschmidt
Journal:  Front Mol Neurosci       Date:  2022-08-02       Impact factor: 6.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.